Is Curis, Inc. (CRIS) a Buy, Sell, or Hold?
NASDAQ : CRIS
Curis, Inc. — News
$4.02 USD
-$0.39 (-8.84%)
- Volume
- 69.17K
- Average Volume
- 166.83K
- Market Capitalization
- $7.83M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $39.00
- Year Low
- $3.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
| Source | Headline |
|---|---|
|
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia (CLL). prnewswire.com - 2026-07-30 08:00:00 |
|
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. benzinga.com - 2026-07-24 14:03:48 |
|
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript seekingalpha.com - 2026-07-22 13:50:25 |
|
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. benzinga.com - 2026-07-22 13:04:16 |
|
Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass. prnewswire.com - 2026-07-22 07:00:00 |
|
Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study. prnewswire.com - 2026-07-06 09:30:00 |
|
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever gurufocus.com - 2026-06-26 10:00:00 |
|
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia. prnewswire.com - 2026-06-26 09:42:00 |
|
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-13 04:20:45 |
|
Curis Provides First Quarter 2026 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass. prnewswire.com - 2026-05-12 16:00:00 |
